408results about "Cell encapsulation" patented technology

The invention is directed to methods and systems for carrying out one or more highly multiplexed cellular assays. In some embodiments, one or more channels of a fluidic device are provided with photopolymerizable polymer precursors and cells randomly disposed on a surface, after which positions of cells are measured by a detector, hydrogel chambers are synthesized by photopolymerization to enclose individual cells, and channels are loaded with assay reagents. Assay signals indicative of desired cellular characteristics can be generated for each of the enclosed cells.

Compositions for preventing or limiting surface fouling as well as evaporation and methods for their use in air-matrix digital microfluidics (DMF) apparatuses are described. A mobilizing wax material may be used to selectively encapsulate a reaction droplet in the air gap of the apparatus, which permits the at least partially encapsulated reaction droplet to be portable within the DMF apparatus. Additional aqueous droplets may be combined with the encapsulated droplet, by merging with an aqueous droplet having a coating of a secondary material (e.g., an oil or other hydrophobic material) that may allow combining of the droplets. The compositions may be additionally useful in non-DMF applications such as laboratory protocols for hybridization, ligation and amplification.

A high-throughput microfluidics-based fluorescence activated droplet sorting (FADS) system provides activation, sorting, and feeder cell-free expansion of NK cells that are enriched for killing activity. The NK cells are activated and identified based on their ability to kill target cells, such as tumor cells, without prior sensitization. The diversity of endogenous NK cells can be overcome to allow selection of a highly effective population of cells for therapeutic use, such as in the treatment of cancer.

To provide non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of making and using the same.SOLUTION: The present application provides non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates, methods of making the 3D BADSC aggregates, and methods of using the 3D BADSC aggregates. Also provided herein is an encapsulation system comprising non-naturally occurring 3D brown adipose-derived stem cell aggregates. The 3D brown adipose-derived stem cell aggregate may comprise brown adipose-derived stem cells that express one or more brown adipocyte gene in the absence of differentiation medium.SELECTED DRAWING: None

The present application provides non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates, methods of making the 3D BADSC aggregates, and methods of using the 3D BADSC aggregates.

The disclosure provides synthetic cytotoxic cells, comprising a hydrogel microsphere and a TNF-related apoptosis-inducing ligand (TRAIL), or active fragment thereof. In aspects, the TRAIL or active fragment thereof is attached to the surface of the hydrogel microsphere. The disclosure further provides methods of preparing the synthetic cytotoxic cells and methods of use thereof in the treatment of cancer.

A composition comprising decellularized extracellular matrices, hydrogels comprising the same, and methods of making the same are disclosed.

Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and / or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and / or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.

The present invention relates to a method for culturing skin-derived stem cells and uses thereof, and to a method for culturing skin-derived stem cells; skin-derived stem cells produced by the method; a pharmaceutical composition for skin regeneration or wound treatment comprising the skin-derived stem cells produced by the method, a culture thereof, or cells differentiated from the skin-derived stem cells as an active ingredient; a quasi-drug composition; and a cosmetic composition. According to the culture method of the present invention, stem cells can be effectively isolated and obtained from skin tissue. The obtained skin-derived stem cells have excellent pluripotency and self-renewal ability, and have excellent skin regeneration and wound treatment effects, and can therefore be usefully used for skin regeneration and wound treatment or improvement applications.

Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and / or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and / or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.

Provided herein are methods for coating a microparticle, cell, or therapeutic agent with a biomimetic zona pellucida (BZP). Also provided herein are BZP-coated cells prepared using the enclosed methods. The methods for using the BZP-coated microparticle to treat diabetes are also provided.

Disclosed herein are devices for encapsulating biological cells and are suitable to be implanted into a subject. In different aspects of the disclosure, the devices may comprise a plurality of polymer layers. In one aspect, a device comprises a first polymer layer and a second polymer layer. In some cases, the first polymer layer may be a nanoporous polymer layer. In some cases, the second polymer layer may be a macroporous polymer layer. The first and second polymer layers may define a lumen for enclosing a population of cells. The devices may be used to transplant cells producing therapeutic agents into a subject (e.g., for the treatment of a disease).

Provided herein are devices and methods for improved oxygenation of biological cells transplanted into a biological subject. The devices and methods may be used to promote vascularization to a transplantation site of the biological subject, and / or may be used to improve survival and functionality of cells contained within an encapsulation device.

Provided herein are methods utilizing microfluidics for the oxygen-controlled generation of microparticles and hydrogels having controlled microparticle sizes and size distributions and products from provided methods. The included methods provide the generation of microparticles by polymerizing an aqueous solution dispersed in a non-aqueous continuous phase in an oxygen-controlled environment. The process allows for control of size of the size of the aqueous droplets and, thus, control of the size of the generated microparticles which may be used in biological applications.

There is provided a hydrogel, such as a functionalized hydrogel, for use in the expansion and / or differentiation of cells, that are encapsulated within the three-dimensional structure of the hydrogel. In some aspects of the invention, the hydrogel better mimics the thymus microenvironment than prior hydrogels for T cell expansion and differentiation and can be used in the expansion and differentiation of HSPCs, HSCs or PCs or combinations thereof in the production of T cells, T-cell committed precursors or progenitor cells and in methods for producing mature T cells. Methods of making the hydrogels, methods of culturing the cells in the hydrogel and uses of the hydrogels and cells produced are also described.

The present invention relates to a specific liver microtissue comprising at least three different phenotypes of liver cells obtained from induced pluripotent stem cells encapsulated in a single three-dimensional closed microcompartment. The invention also relates to a method for preparing the liver micro-tissue and application of the liver micro-tissue in treating or preventing liver failure.

Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and / or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and / or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.

The present disclosure provides methods of making tissue-derived epithelial organoids. In particular, the present disclosure provides a tissue-derived epithelial organoid embedded in a hydrogel suspended in a culture medium. The present disclosure further provides methods of using such organoids.

Embodiments of the present invention may provide protecting, preserving, and even repairing biological cells during in vitro processing. A uniform environment such as a protective layer with exogeneous lipids may be formed around biological cells which may interact with the plasma membranes of the cells.

Systems, methods, and compositions provided herein relate to preparation of beads encapsulating genetic material. Some embodiments include preparation of nucleic acid libraries within the bead, wherein the bead includes pores that allow diffusion of reagents while retaining genetic material.

A macroencapsulation device and associated manufacturing method are described in which a bonded membrane of the device may be attached to an associated frame in an arrangement that provides stress relief between the frame and a seal perimeter of the bonded membrane, and the seal perimeter may be disposed radially inward from an outer periphery of the membrane such that when the membrane is attached to a corresponding peripheral frame, the seal perimeter is spaced radially inward from the frame and an unbonded portion of one or more membranes is provided between the frame and the seal perimeter.

A therapeutic device includes a tubular body including a lumen extending therethrough, a wall of the tubular body including a first composite layer, a second composite layer; and a reservoir between the first and second composite layers, the reservoir being configured to receive and contain a biological moiety. In another embodiment, a therapeutic device includes a toroidal therapeutic device having a first opening therein and a hollow interior, the toroidal therapeutic device having a wall including a first permeable composite layer, a second permeable composite layer, and a reservoir between the first and second composite layers, the reservoir being configured to receive and contain a biological moiety.

Systems and methods consistent with the present invention generally relate to microorganospheres (MOSs), and methods and apparatuses for forming and using MOSs. More particularly, in some embodiments, systems and methods consistent with the invention relate to the methods and apparatuses for forming and using MOSs generated from hepatocytes. MOSs that are generated from hepatocytes are suitable for testing liver toxicity and drug induced liver injury effects of various agents.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

The present invention relates to specific liver microtissues comprising hepatocytes of at least three different phenotypes derived from induced pluripotent stem cells encapsulated in a single three-dimensional closed microcompartment. The present invention also relates to methods for preparing such liver microtissues and their use in the treatment or prevention of liver failure.

The present disclosure provides thymic cells, thymic organoids, and animal models comprising such thymic cells and thymic organoids. It also provides methods for inducing differentiation of pluripotent stem cells into definitive endoderm (DE), anterior foregut endoderm (AFE), ventral pharyngeal endoderm (VPE), thymic epithelial progenitor (TEP) cells, thymic epithelial cells (TECs) and thymic organoids in vitro and in vivo.

The invention relates to a three-dimensional cellular microcompartment or an assembly of three-dimensional cellular microcompartments of ovoid, cylindrical, spheroidal or spherical shape or substantially ovoid, cylindrical, spheroidal or spherical shape, the smallest dimension of which is between 200 and 400 μm, comprising an external hydrogel layer defining an internal part, said internal part having a granzyme B content of less than 1 μg / ml of medium and comprising between 500 and 5000 lymphocytes forming a three-dimensionally grouped culture. The invention also relates to a method for producing such a microcompartment or microcompartment assembly.